Institutional Highlights

The Institute's primary asset is a team of more than 55 highly motivated scientists, with a majority of them having several years of training in world renowned laboratories. Supported by more than 300 well trained technical staff and graduate students, these scientists have built strong peer credibility both in basic and application-oriented broad thematic areas of Molecular biology and microbial genetics, Cell biology and immunology, Protein science and engineering, and Fermentation technology and applied microbiology. These overarching focus areas required enabling research facilities, structures and practices which IMTECH has created over the years, recognized nationally to be the best, and globally at par with the best. This required a visionary approach and objectives with a long term mandate of scientific relevance.

IMTECH's team of scientists having cutting edge R&D expertise in the areas of: Cloning & expression of recombinant / engineered proteins & their scale-up, Understanding / manipulating proteins and their engineering, Protein structure determination through X-ray crystallography, Molecular microbiology of pathogens especially with respect to drug resistance & vaccine development, Immunology of infectious diseases, Yeast Genetics, Screening of microorganisms for novel enzymatic activities and strain improvement, Bioinformatics & high end computational biology, Microbial taxonomy and metagenomics, and allied areas like technology and business management and intellectual property protection.

CSIR-IMTECH Signed MoU with Merck to establish a High-End Skill Development Centre

CSIR-IMTECH Signed MoU with Merck to establish a High-End Skill Development Centre

CSIR-Institute of Microbial Technology(IMTECH) announced a new partnership with Merck, a leading German science and technology company, to

CSIR-IMTech Signs MOU with Johnson & Johnson for collaborative research on TB

CSIR-IMTech Signs MOU with Johnson & Johnson for collaborative research on TB

CSIR-IMTech has entered into a new collaboration with global pharmaceutical company, Johnson and Johnson   for development of new

Technology available for licensing

Technology available for licensing

The BCG vaccine provides immunity to TB only during childhood, this protection lapses as time goes by and the vaccinated children reach

Technologies transferred and/or commercialized

Technologies transferred and/or commercialized

Natural Streptokinase, Recombinant Streptokinase, Clot-Specific Streptokinase, Anti thrombotic clot busters with optimised half-life,

  • 2